Overactive urinary (OAB) syndrome affects millions of individuals worldwide. The personal, financial and economic cost of OAB is enormous. Therefore, novel treatments are required. Theis Editorial focus highlights the recent study by Hristov and co-workers on the role of TRPM4 in human urinary bladder function.
